The C9orf72 hexanucleotide repeat expansion presents a challenge for testing laboratories and genetic counseling
- 23 March 2019
- journal article
- review article
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 20 (5-6) , 310-316
Abstract
C9orf72 hexanucleotide repeat expansions are the most common known cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Genetic testing for C9orf72 expansions in patients with ALS and/or FTD and their relatives has become increasingly available since hexanucleotide repeat expansions were first reported in 2011. The repeat number is highly variable and the threshold at which repeat size leads to neurodegeneration remains unknown. We present the case of an ALS patient who underwent genetic testing through our Motor Neurone Disease Clinic. We highlight current limitations to analysing and interpreting C9orf72 expansion test results and describe how this resulted in discordant reports of pathogenicity between testing laboratories that confounded the genetic counselling process. We conclude that patients with ALS or FTD and their at-risk family members, need to be adequately counselled about the limitations of current knowledge to ensure they are making informed decisions about genetic testing for C9orf72. Greater collaboration between clinicians, testing laboratories and researchers is required to ensure risks to patients and their families are minimised.Keywords
Funding Information
- National Health and Medical Research Council of Australia
- NHMRC (APP1095215)
This publication has 57 references indexed in Scilit:
- Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosisCurrent Opinion in Neurology, 2018
- Patients with sporadic and familial amyotrophic lateral sclerosis found value in genetic testingMolecular Genetics & Genomic Medicine, 2017
- Genetic screening in sporadic ALS and FTDJournal of Neurology, Neurosurgery & Psychiatry, 2017
- Predictive genetic testing for amyotrophic lateral sclerosis and frontotemporal dementia: genetic counselling considerationsAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017
- Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for cliniciansGenetics in Medicine, 2017
- Patients with Amyotrophic Lateral Sclerosis Have High Interest in and Limited Access to Genetic TestingJournal of Genetic Counseling, 2016
- Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAsNeuron, 2016
- Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutationsAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015
- Genetics of dementia: Update and guidelines for the clinicianAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012
- Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9pActa Neuropathologica, 2012